Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 71 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... June 17, 2022 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 What to Know About Mastectomy With Flat Closure After a Breast... January 27, 2022 Load more HOT NEWS When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... EMA Recommends Extending Indications for Durvalumab Recognising the essential role of clinical research nurses Common anti-inflammatory drug could boost cancer immunotherapy
